Renascience Inc

Renascience Inc maintains a strong liquidity position, with cash and equivalents amounting to ¥1,799.8 million, representing 96.2% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is robust, with free cash flow of ¥112.7 million and total liabilities of ¥151.2 million, indicating a liquidity buffer of 74.5%. The current ratio of 12.38 further underscores the company's ability to meet short-term obligations. Profitability metrics show a return on equity (ROE) of 6.59% and a return on assets (ROA) of 6.06%, both below the industry median for pharmaceutical firms, which typically exceed 10% ROE and 8% ROA. The company's operating margin is 10.85% (¥14.4 billion operating income on ¥132.7 billion revenue), which is also below the median for the sector. Geographically, Renascience Inc's revenue is concentrated in Japan, with no disclosed international segments. The company's business is entirely within the pharmaceuticals and medical devices space, with no diversification into other therapeutic areas or geographies. Growth trajectory is modest, with no disclosed revenue growth in the latest period. The company's outlook for the current fiscal year shows a flat revenue trend, with no significant changes expected in the next fiscal year. This is consistent with the company's focus on R&D for aging-related diseases, which typically have long development cycles. Risk factors are minimal, with no immediate liquidity or dilution flags detected. The company has no long-term debt and a low debt-to-equity ratio of 0.0, indicating a conservative capital structure. There is no dilution potential in the near term, as shares outstanding remain unchanged between basic and diluted. Recent events include the continued development of drugs for non-infectious aging-related diseases, with no significant regulatory or legal challenges disclosed in the latest filings. The company's focus on R&D and collaboration with physicians remains a key strategic direction.